RANKL抑制剂促进类风湿关节炎骨侵蚀愈合的HR-pQCT研究
这项为期24个月的随机双盲安慰剂对照试验评估了地舒单抗对病情稳定的RA患者第2-4掌指骨头骨侵蚀愈合的影响。12个月时两组HR-pQCT骨侵蚀参数变化无差异,但24个月时地舒单抗组新发骨侵蚀和骨侵蚀进展比例显著低于安慰剂组,骨侵蚀愈合比例显著更高。
要点
- 地舒单抗60mg每6个月皮下注射可减少24个月新发骨侵蚀和骨侵蚀进展
- 地舒单抗组24个月骨侵蚀愈合比例显著高于安慰剂组(20% vs 6%)
- 12个月时两组HR-pQCT骨侵蚀参数变化无显著差异
核心结论
- 尽管12个月时未观察到骨侵蚀参数差异,地舒单抗在24个月时对HR-pQCT骨侵蚀修复优于安慰剂。
研究设计与样本
- 随机、安慰剂对照、双盲研究,RA患者按1:1随机接受地舒单抗60mg或安慰剂皮下注射每6个月一次,共24个月。
- 纳入DAS28≤5.1的RA患者,24个月时对98例患者的HR-pQCT图像进行分析。
主要发现
- 24个月时安慰剂组新发骨侵蚀(19% vs 9%,p=0.009)和骨侵蚀进展(18% vs 8%,p=0.019)均多于地舒单抗组。
- 24个月时地舒单抗组骨侵蚀愈合比例显著高于安慰剂组(20% vs 6%,p=0.045)。
- 12个月时两组HR-pQCT骨侵蚀参数变化相似。
- 12和24个月时两组HR-pQCT关节间隙参数、van der Heijde-Sharp侵蚀评分、DAS28和HAQ-DI均无显著变化。
- 全程约三分之一患者维持持续低疾病活动度。
关键数值与推荐
- 主要结局为12个月时HR-pQCT上第2-4掌指骨头的骨侵蚀愈合。
- 地舒单抗用法为60mg皮下注射每6个月一次,持续24个月。
- 纳入标准为DAS28≤5.1的RA患者。
临床怎么用
- 对于病情稳定的RA患者,地舒单抗可能有助于减少24个月新发骨侵蚀和骨侵蚀进展并促进骨侵蚀愈合。
- 12个月时HR-pQCT骨侵蚀参数未见组间差异,评估RANKL抑制对骨侵蚀修复的效应可能需要更长观察时间。
局限性
- 24个月时HR-pQCT图像分析仅纳入98例患者。
- 全程仅约三分之一患者维持持续低疾病活动度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of denosumab on erosion healing at 2-4 metacarpophalangeal (MCP) head as determined by high-resolution peripheral quantitative CT (HR-pQCT) in patients with rheumatoid arthritis (RA) with stable disease. METHODS: This was a randomised, placebo-controlled, double-blind study. Patients with RA with disease activity score 28 joints (DAS28) ≤5.1 were randomised (1:1) to subcutaneous denosumab 60 mg or placebo once every 6 months for 24 months. The primary outcome was erosion healing at MCP 2-4 on HR-pQCT at 12 months. The effects of denosumab on erosion and joint space parameters on HR-pQCT and radiographs, disease activity and health assessment questionnaire-disability index (HAQ-DI) were also examined. RESULTS: At 24 months, HR-pQCT images were analysed in 98 patients. One-third of the patients achieved sustained low disease activity throughout the study. At 12 months, changes in erosion parameters on HR-pQCT were similar between the two groups. At 24 months, new erosions (19% vs 9%, p=0.009) and erosion progression (18% vs 8%, p=0.019) were more common in the placebo group than the denosumab group. Erosion healing was seen in a significantly higher proportion of patients in the denosumab group (20% vs 6%, p=0.045) at 24 months. No significant changes in joint space parameters on HR-pQCT, van der Heijde-Sharp erosion score, DAS28 and HAQ-DI were observed in the two groups at 12 and 24 months. CONCLUSION: Although no differences in erosion parameters were observed at 12 months, denosumab was more efficacious than placebo in erosion repair on HR-pQCT after 24 months. TRIAL REGISTRATION NUMBER: NCT03239080.
引用
- So H, Cheng IT, Lau SL, et al. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021. PMID: 33811034. doi:10.1136/annrheumdis-2021-219846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。